Bio-Rad Laboratories (BIO) AI Stock Analysis

• Market Cap: $8.67B
• Dividend Yield: N/A
• Average Volume (3M): 222.25K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: -0.88%
• EPS Growth: 10.93%
• Country: US
• Employees: 7,700
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 2.26
• Shares Outstanding: 21,906,399
• 10 Day Avg. Volume: 158,934
• 30 Day Avg. Volume: 222,249
• PEG Ratio: -0.03
• Price to Book (P/B): 1.41
• Price to Sales (P/S): 3.61
• P/FCF Ratio: 34.82
• Enterprise Value/Market Cap: 0.87
• Enterprise Value/Revenue: 2.94
• Enterprise Value/Gross Profit: 5.63
• Enterprise Value/Ebitda: -12.11
• 1Y Price Target: $357.50
• Price Target Upside: 11.20% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 10.21
• Revenue Forecast (FY): $2.59B

• Rating: 58 Neutral
• Price Target: $332.00 ▲(3.27% Upside)

Bio-Rad Laboratories faces significant financial challenges with declining revenue and profitability, impacting its overall score. Technical analysis shows positive momentum, providing some support. Valuation remains unattractive due to negative earnings. The earnings call suggests cautious optimism, but operational challenges persist.

Positive Factors

Process Chromatography Growth

The strong growth in process chromatography indicates a robust demand for Bio-Rad's products in this area, suggesting a competitive advantage and potential for sustained revenue growth in the future.

Droplet Digital PCR Strategy

Advancements in the Droplet Digital PCR strategy, including global sales training and partnerships, enhance Bio-Rad's market position in precision diagnostics, supporting long-term growth.

Operating Margin Improvement

The increase in operating margin reflects effective cost management, which can lead to improved profitability and financial health over the long term.

Negative Factors

Life Science Segment Decline

The decline in the Life Science segment indicates challenges in key markets, potentially impacting Bio-Rad's revenue and market share if not addressed.

Gross Margin Decline

A decline in gross margin due to higher material costs suggests pressure on profitability, which could affect long-term financial performance if not mitigated.

Free Cash Flow Decrease

The decrease in free cash flow indicates potential liquidity challenges, which could limit Bio-Rad's ability to invest in growth opportunities and manage debt.

Bio-Rad Laboratories Business Overview & Revenue Model

Company Description

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

How the Company Makes Money

Bio-Rad generates revenue through the sale of a diverse portfolio of products primarily in the life sciences and clinical diagnostics markets. The Life Science segment contributes significantly to revenue through the sale of reagents, instruments, and consumables utilized in research and drug development. Key revenue streams include products for protein purification, gene expression analysis, and cellular biology. In the Clinical Diagnostics segment, the company earns revenue from diagnostic tests and assays that aid in disease detection and management, including immunology, blood typing, and infectious disease testing. Additionally, Bio-Rad has established partnerships with various healthcare organizations and research institutions, which help expand its market reach and drive sales. The company also benefits from recurring revenue through consumables and maintenance contracts tied to its instruments, creating a stable income stream.

Bio-Rad Laboratories Financial Statement Overview

Summary

Bio-Rad Laboratories is facing financial challenges with declining revenue and profitability. The income statement shows negative net profit margins and operational inefficiencies. The balance sheet is stable with low leverage, but negative ROE is concerning. Cash flow generation is mixed, with a need for improvement in free cash flow.

Income Statement

Bio-Rad Laboratories has experienced a challenging period with declining revenue and profitability. The TTM data shows a revenue growth rate of 12.8%, but the net profit margin is negative, indicating losses. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Historical data shows a downward trend in revenue and profitability, with significant losses in recent years.

Balance Sheet

The company's balance sheet shows a relatively low debt-to-equity ratio, indicating conservative leverage. However, the return on equity is negative, reflecting the company's inability to generate profits from its equity base. The equity ratio is strong, suggesting a solid capital structure, but the negative ROE is a concern.

Cash Flow

Cash flow analysis reveals a mixed picture. The operating cash flow to net income ratio is healthy, indicating good cash generation relative to reported losses. However, free cash flow growth has been negative in the TTM period, and the free cash flow to net income ratio is moderate. The company needs to improve its cash flow generation to support operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.56B	2.57B	2.67B	2.80B	2.92B	2.55B
Gross Profit	1.34B	1.38B	1.43B	1.57B	1.64B	1.44B
EBITDA	-621.30M	-2.14B	-654.80M	-4.49B	5.59B	5.08B
Net Income	-675.90M	-1.84B	-637.32M	-3.63B	4.25B	3.81B
Balance Sheet
Total Assets	9.70B	9.36B	12.30B	13.50B	17.80B	12.97B
Cash, Cash Equivalents and Short-Term Investments	1.42B	1.66B	1.61B	1.79B	869.92M	991.12M
Total Debt	1.40B	1.37B	1.41B	1.39B	223.38M	225.74M
Total Liabilities	2.96B	2.79B	3.56B	3.89B	4.11B	3.09B
Stockholders Equity	6.74B	6.57B	8.74B	9.62B	13.69B	9.88B
Cash Flow
Free Cash Flow	336.75M	266.20M	218.26M	80.29M	535.72M	476.41M
Operating Cash Flow	491.45M	455.20M	374.94M	194.45M	669.46M	584.97M
Investing Cash Flow	-186.04M	-160.20M	20.21M	-1.21B	-797.38M	-69.89M
Financing Cash Flow	-312.75M	-218.80M	-425.65M	973.58M	-55.43M	-523.04M

Bio-Rad Laboratories Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 321.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIO, the sentiment is Positive. The current price of 321.5 is above the 20-day moving average (MA) of 314.38, above the 50-day MA of 308.78, and above the 200-day MA of 268.26, indicating a bullish trend. The MACD of 3.52 indicates Negative momentum. The RSI at 54.13 is Neutral, neither overbought nor oversold. The STOCH value of 73.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BIO.

Bio-Rad Laboratories Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSX	79 Outperform	$150.59B	54.33	12.66%	―	21.62%	54.80%
EW	79 Outperform	$50.29B	36.90	13.59%	―	0.19%	65.58%
MDT	74 Outperform	$135.03B	28.45	9.81%	2.73%	5.34%	13.15%
DXCM	69 Neutral	$24.75B	35.33	30.63%	―	14.21%	5.66%
BIO	58 Neutral	$8.67B	-13.23	-9.50%	―	-0.88%	10.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHG	50 Neutral	$26.76B	―	―	3.13%	-0.76%	-55.03%

Bio-Rad Laboratories Corporate Events

Bio-Rad Laboratories’ Earnings Call Highlights Resilience

Bio-Rad Laboratories’ recent earnings call painted a picture of resilience amidst challenges. The company demonstrated strength in areas like process chromatography and droplet digital PCR strategy, despite facing headwinds in the Life Science segment and experiencing a decline in gross margins. The decision to maintain full-year guidance reflects a sense of cautious optimism from Bio-Rad’s leadership.

Bio-Rad Laboratories Reports Stable Q3 2025 Results

Bio-Rad Laboratories, Inc. is a prominent player in the life science research and clinical diagnostics sectors, known for its innovative products that advance scientific research and healthcare diagnostics globally.

Bio-Rad Reports Q3 2025 Financial Results Amid Challenges

On October 29, 2025, Bio-Rad Laboratories reported its financial results for the third quarter ended September 30, 2025. Despite challenges in academic research and biotech funding, the company achieved a slight increase in revenue to $653.0 million, up 0.5% from the previous year. However, a change in the fair market value of its investment in Sartorius AG led to a significant net loss of $341.9 million. The company maintained its full-year 2025 financial outlook, expecting non-GAAP, currency-neutral revenue growth of 0 to 1.0 percent.

The most recent analyst rating on (BIO) stock is a Buy with a $366.00 price target. To see the full list of analyst forecasts on Bio-Rad Laboratories stock, see the BIO Stock Forecast page.

Bio-Rad Laboratories Mourns Loss of Co-Founder Alice Schwartz

On September 29, 2025, Bio-Rad Laboratories announced the passing of its co-founder and Director Emeritus, Alice N. Schwartz, on September 25, 2025, at the age of 99. Alice Schwartz, who co-founded the company in 1952, played a pivotal role in its growth and success, particularly in the development of Bio-Rad’s first test kit for thyroid function, which marked the company’s entry into clinical diagnostics. Her leadership and passion for scientific discovery have left a lasting legacy at Bio-Rad and in the broader scientific community.

The most recent analyst rating on (BIO) stock is a Hold with a $288.00 price target. To see the full list of analyst forecasts on Bio-Rad Laboratories stock, see the BIO Stock Forecast page.

Bio-Rad Hosts Webinar on Digital PCR Advancements

On August 26, 2025, Bio-Rad Laboratories hosted an informational webinar on its Droplet Digital PCR product portfolio, highlighting the technology’s precision and scalability. The event, led by company executives, aimed to showcase Bio-Rad’s leadership in digital PCR and its potential to drive future growth by transitioning customers from traditional PCR methods to its advanced digital solutions.

The most recent analyst rating on (BIO) stock is a Buy with a $336.00 price target. To see the full list of analyst forecasts on Bio-Rad Laboratories stock, see the BIO Stock Forecast page.